Stuart Gander succeeds Jonas Jarvius as CEO of Q-linea (publ) (OMX: QLINEA). Stuart Gander brings extensive experience from leading positions in the global healthcare industry, with a focus on diagnostics and medical technologies.

Through his management consulting background, he has supported companies on a range of operational challenges with a focus on driving sustainable change and growth, based on building strong and motivated teams. Stuart Gander is a Canadian citizen, has previously been working 15 years in Sweden, is currently living in the USA but will relocate to Sweden within the next 18 months.

"I look forward to building on Q-linea's technical strengths and the competence that exists within the company and at the same time adapting and accelerating our capabilities for the commercialization phase we have begun. We have already shown that we have a very competitive product in an area that we expect to grow strongly in the next few years. It is now up to us at Q-linea to bring our technology to hospitals and labs so patients with severe infections can be treated more quickly while simultaneously reducing reduce healthcare costs," says Stuart Gander, incoming CEO of Q-linea.

"We, myself and the rest of the board, are looking forward to working with Stuart. We are convinced that his international background from leading positions, both at Boston Consulting Group and in the diagnostics industry will be a success factor for Q-linea and its shareholders. We are convinced that Stuart will successfully lead the company through our commercialization phase and benefit from the strong technical foundation that has been systematically built up by the Q-linea team over a long period of time," says Erika Kjellberg Eriksson, chairman of the board for Q-linea.

For more information, please contact:

Jonas Jarvius, CEO, Q-linea AB
Jonas.Jarvius@qlinea.com
+46 (0) 70-323 77 60

Christer Samuelsson, CFO /IR, Q-linea AB
Christer.Samuelsson@qlinea.com
+46 (0) 70-600 15 20

About Q-linea

Q-linea is an innovative infection diagnostics company that primarily develops instruments and disposables for rapid and reliable infection diagnostics. Our vision is to help save lives by ensuring antibiotics continue to be an effective treatment for future generations. Q-linea develops and delivers preferred solutions for healthcare providers, enabling them to accurately diagnose and treat infectious disease in the shortest possible time. The company's lead product ASTar® is a fully automated instrument for antibiotic susceptibility testing (AST), giving a susceptibility profile within six hours directly from a positive blood culture. For more information, please visit www.qlinea.com.

This information is information that Q-linea is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 2024-01-22 13:30 CET.

Attachments

Stuart Gander takes over as CEO of Q-linea on March 1, 2024

© Modular Finance, source Nordic Press Releases